ABVC BioPharma, Inc. ABVC
1.13
0.04
3.67%
as of 25 Sep
- Market cap
- $34.0M
- P/E
- 0.0×
Follow ABVC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (65.32%) | (83.01%) | (112.81%) | (52.27%) |
+8 more TTM periods Free account |
|
| (39.88%) | (49.85%) | (55.30%) | (32.92%) | ||
ROIC |
(33.45%) | (39.75%) | (37.54%) | (26.04%) | |
Return on Tangible Assets |
(94.14%) | (106.78%) | (86.22%) | (61.03%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.10) | (0.13) | (0.15) | (0.13) | |
Free Cash Flow |
(2.69) | (3.34) | (2.99) | (3.10) | |
Piotroski F-Score |
— | — | — | 5.00 | |
| Other line items | |||||
Cash ROIC |
(21.76%) | (25.64%) | (20.33%) | (20.12%) | |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
— | — | — | 0.00 | |
Days of Inventory on Hand |
— | — | — | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 9.51% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 424.32% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 239.17% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.38 | 0.39 | 0.38 | 0.53 | |
Depreciation/Fixed assets |
0.04 | 0.04 | 0.04 | 0.01 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.06 | |
Operating CF per Share |
(0.10) | (0.13) | (0.15) | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | (450.26%) |
Columns are period end dates